i'm impressed, page-18

Hi Minter

I wouldn't be particularly concerned about the lack of a mention for Oral Gardasil. It was always a non-core, peripheral project with a lengthy development timeframe. Keeping it simmering on the back burner to preserve cash for Cvac development makes good commercial sense.

I personally doubt PRR would have any intention to go to market with this themselves in any case. Rather more likely to eventually license the oral vaccine to the incumbent pharma (Merck) as a adjunct to their injectible product, as they already have the marketing & distribution network in place. Very expensive to replicate that infrastructure from scratch.